Calcutta HC Confirms KMC Can Revise Property Valuation to Levy Tax In ?11.24 Crore Dispute || Bom HC Cancels Bail of Accused Supplying Fake Medicines, Says it Weakens Public Trust in Healthcare || MP HC: Oral, Anal Sex Between Married Couples Not Punishable under Section 377 IPC || SC Says Respect For Higher Court Orders a Basic Principle, Rebukes Authority For Revisiting Order || SC: Merits of Foreign Arbitral Awards Cannot be Re-Examined During Enforcement Proceedings || SC: Failure to Sign Charge Sheet Doesn’t Invalidate Trial if Charges Were Properly Read to Accused || Delhi HC: Bipolar Disorder Alone Does Not Qualify as Medical Disability Without Benchmark Criteria || Kerala HC: Excommunicating Knanaya Catholics For Marrying Outside the Community is Unconstitutional || Kerala HC: Temporary Use of Religious Land For Public Infrastructure is Not a ‘Transfer’ under Law || P&H HC: Habeas Plea in Child Custody Case Not Maintainable if Child is With Natural Guardian and Safe

Merck Sharp & Dohme Corporation & Anr. v. Glenmark Pharmaceuticals Ltd. - (High Court of Delhi) (07 Oct 2015)

Delhi High Court rules in favour of Merck for its diabetes drug

Intellectual Property Rights

The Delhi High Court restrained Glenmark from selling any drug containing Sitagliptin or its derivate. Sitagliptin is the active ingredient used in ‘Januvia’, Merck’s once-daily pill used to lower blood sugar levels in people with Type II diabetes. It had claimed that Glenmark had infringed its patent in the specific chemical. The court dismissed contentions that Glenmark’s product, ‘Zita’, was different from Merck’s product.

Relevant : Read the decision in Merck Sharp & Dohme Corporation v. Glenmark Pharmaceuticals Ltd.

Tags : GLENMARK MERCK PATENT DIABETES

Share :